The EC has granted marketing authorisation for AbbVie’s Tepkinly in combination with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma.

Servier’s head of business development Frederic Scaerou discusses the French company’s recent string of dealmaking.

Through predictive modelling, AI supports target identification, prediction of physicochemical properties and formulation strategy selection.

Fresh with a rebrand, Cyllene will advance gene therapies built on a platform that uses a modified form of the herpes virus for delivery.

Vertex is to acquire Crinetics Pharmaceuticals in a transaction valued at nearly $10bn, or $8.8bn net of estimated cash acquired.

The UK Government has prioritised life science sector growth, but industry members have called for more funding.

Besins Healthcare has expanded its pharmaceutical operations with the acquisition of UniD Manufacturing, which specialises in long-acting drug delivery technologies.

Roche’s breast cancer agreement with Astex is one of several oncology deals the Swiss pharma giant has inked in recent years.

Novartis has signed an agreement to purchase Myricx Bio, a UK-based biotechnology company, in a transaction valued at up to $1.5bn.

Paris is emerging as a focal point for Europe’s next phase in oncology, as science, capital and industry converge at Campus Grand Parc.

WHO is sponsoring a trial testing drugs for Bundibugyo virus, while adding the first Ebola diagnostic test to its emergency use list.

The UK-US pharmaceuticals deal could cost the National Health Service (NHS) around £45bn ($60bn) within a decade and divert resources away from essential services, an analysis has suggested. The UK ...